EMA plans guidance on process validation of biotechnology-derived active substances
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking stakeholder feedback on its plan to develop guidance on the process validation of biotechnology-derived active substances1. The agency's proposal is outlined in a concept paper, on which comments will be accepted until 31 August.